Registration - In-house Corporation

Hoffmann-La Roche Limited / BRIGITTE NOLET, PRESIDENT AND CHIEF EXECUTIVE OFFICER

Registration Information

In-house Corporation name: Hoffmann-La Roche Limited
Previous in-house corporation names
Responsible Officer Name: BRIGITTE NOLET, PRESIDENT AND CHIEF EXECUTIVE OFFICER
Responsible Officer Change History
Initial registration start date: 2001-01-18
Registration status: Active
Registration Number: 952745-64

Associated Communications

Total Number of Communication Reports: 479

Monthly communication reports in the last 6 months: 8

Version 30 of 67 (2015-10-19 to 2016-09-30)

Registration versions:

Version 30 of 67 (2015-10-19 to 2016-09-30)

Lobbying Information

Subject Matters

Aboriginal Affairs
Agriculture
Budget
Constitutional Issues
Consumer Issues
Defence
Economic Development
Education
Employment and Training
Energy
Environment
Financial Institutions
Fisheries
Forestry
Government Procurement
Health
Immigration
Industry
Infrastructure
Intellectual Property
Internal Trade
International Relations
International Trade
Justice and Law Enforcement
Labour
Regional Development
Research and Development
Science and Technology
Small Business
Sports
Taxation and Finance
Transportation

Subject Matter Details

Legislative Proposal, Bill or Resolution

Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry
Patent Act as it relates to further changes affecting patent term restoration
User Fees Act with respect to cost recovery

Legislative Proposal, Bill or Resolution, Policies or Program

Food and Drugs Act as it relates to modernization,Protecting Canadians From Unsafe Drugs Act (as it relates to the release of confidential business information)

Policies or Program

Biologics and Genetic Therapies Directorate as it relates to policies affecting the review and approval of submissions
Clinical Trials environment in Canada: operational issues, investment, enrollment
Guidance for Industry: Issuance of Health Professional Communications and Public Communications by Market Authorization Holders and Draft Guidance Document: Triggers for Issuance of Risk Communication Documents for Marketed Health Products for Human Use with respect to communications from manufacturers, health professionals and consumers, to the public via Health Canada and manufacturers, and Product Monographs
Health Canada International Memorandum of Understanding with respect to exchanging data and safety protocols
Health Canada Post Notice of Compliance Change Guidance: Quality with respect to the categorization of a change and the recommended supporting data for any changes to the Quality information associated with a new drug
Implementation of the National Pharmaceutical Strategy as it affects the industry; "National Pharmacare/ universal drug coverage"
Pandemic Planning as it relates to the Task Group on Antiviral Prophylaxis recommendations
Patent Act as it relates to changes to Canada's Access to Medicines Regime
Patented Medicine Prices Review Board in respect of proposed Pricing Guidelines
Progressive Licensing Framework with respect to its development and government consultations
Science and Technology Strategy as it relates to new policies for the pharmaceutical industry
Therapeutic Products Directorate's work as it relates the Guidance for Industry: Management of Drug Submissions with respect to the review and approval of submissions

Policies or Program, Regulation

Creation of pathways for Subsequent Entry Biologics (SEBs) pertaining to Draft Guidance for Sponsors: Information and Submission Requirements for SEBs, regulations and intellectual property policies
Orphan Drug Regulatory Framework as it relates to separate regulatory pathway for drugs for rare diseases

Regulation

Amendments to the Food and Drugs Act Regulations as it relates to further changes to data protection
Data Protection Regulations with respect to its implementation and application to the Food and Drugs Act
Patent Act as it relates to Patented Medicines (Notice of Compliance) Regulations and possible changes to modernize and Right of Appeal

Communication Techniques

Written communication
Oral communication

Government Institutions

Aboriginal Affairs and Northern Development Canada
Agriculture and Agri-Food Canada (AAFC)
Atlantic Canada Opportunities Agency (ACOA)
Canadian Institutes of Health Research (CIHR)
Canadian International Trade Tribunal (CITT)
Canadian Space Agency (CSA)
Canadian Transportation Agency (CTA)
Citizenship and Immigration Canada
Competition Tribunal (CT)
Correctional Service of Canada (CSC)
Employment and Social Development Canada (ESDC)
Environment Canada
Federal Economic Development Agency for Southern Ontario (FedDev)
Federal Office of Regional Development – Quebec (FORD[Q])
Finance Canada (FIN)
Foreign Affairs, Trade and Development Canada
Health Canada (HC)
House of Commons
Industry Canada
Justice Canada (JC)
Members of the House of Commons
National Defence (DND)
National Research Council (NRC)
Natural Resources Canada (NRCan)
Natural Sciences and Engineering Research Council (NSERC)
Office of the Information and Privacy Commissioner (OIPC)
Patented Medicine Prices Review Board (PMPRB)
Prime Minister's Office (PMO)
Privy Council Office (PCO)
Public Health Agency of Canada (PHAC)
Public Safety and Emergency Preparedness Canada (PSEPC)
Public Service Commission of Canada (PSC)
Public Works and Government Services Canada
Revenue Canada (RC)
Royal Canadian Mounted Police (RCMP)
Senate of Canada
Service Canada (ServCan)
Solicitor General Canada (SGC)
Statistics Canada (StatCan)
Transport Canada (TC)
Treasury Board Of Canada Secretariat (TBS)
Veterans Affairs Canada (VAC)
Western Economic Diversification Canada (WD)

In-house Corporation Details

Description of activities

Hoffmann-La Roche Limited deals with the healthcare system in the prevention, screening, diagnosis, treatment and management of acute and long-term disease and supports leading research and development - including clinical research, clinical trials and genetic research.

Responsible officer name and position during the period of this registration

RONNIE MILLER, PRESIDENT AND CHIEF EXECUTIVE OFFICER

Government funding

End date of the last completed financial year: 2014-12-31

List of Government Funding
Government Institution	Funding Received in Last Financial Year	Funding Expected in Current Financial Year
Minister of Economic Development and Trade - Ontario	$7,611,960.00	No

In-house Corporation Contact Information

Address:
7070 Mississauga Road
Mississauga, ON L5N 5M8
Canada

Telephone number: 905-542-5555
Fax number: 905-542-5689

Parent Company Information

F. Hoffmann-La Roche AG
- Grenzacherstrasse 124
  4070 Basle
  Switzerland

Subsidiary Beneficiary Information

Hoffmann-La Roche Limited does not have any subsidiaries that could have a direct interest in the outcome of the undertaking

Lobbyists Details

Senior Officers whose lobbying activities represent less than 20% of their Duties

Christina Archer, Country Head (Canada), Country Clinical Operations NA | No public offices held
Nita Arora, PDG Site Head CCO Regional Head NA | No public offices held
Debbie Knifton, Sr. Manager Government Relations and Health Policy | No public offices held
RONNIE MILLER, PRESIDENT AND CHIEF EXECUTIVE OFFICER | No public offices held
Ilona Torontali, Vice President, Regulatory Affairs and Market Access | No public offices held

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

Angela Behboodi, Director Public Policy | No public offices held
Lisa Chartrand, Director, Regulatory Affairs and Quality Management | No public offices held
Francois Drolet, Director, Business Development (Roche Diagnostics) | No public offices held
Elizabeth Peace, Manager, Government Relations and Health Policy | Public offices held
Gordon Pritchard, Sr. Manager, Government Relations | No public offices held

Hoffmann-La Roche Limited

The following names have been used on or after July 2, 2008

Name	From	To
Hoffmann-La Roche Limited	2008-08-13	current

The following names have been used before July 2, 2008

Hoffmann-La Roche Limited
HOFFMANN-LA ROCHE LIMITED

Hoffmann-La Roche Limited

Responsible Officer History
Responsible Officer Name	From (YYYY-MM-DD)	To (YYYY-MM-DD)
BRIGITTE NOLET	2022-08-01	Current
RONNIE MILLER	2001-01-18	2022-08-01

List of Public Offices Held
Position	Period Held	Last Date Designated Public Office Held
Special Assistant (Ontario) Human Resources Development Canada, Minister's Office	May 2000 to January 2001	Not a designated office

Date Modified:: 2025-04-30

Search and menus

Language selection

Registration - In-house Corporation

Hoffmann-La Roche Limited / BRIGITTE NOLET, PRESIDENT AND CHIEF EXECUTIVE OFFICER

Registration Information

Associated Communications

Version 30 of 67 (2015-10-19 to 2016-09-30)

Version 30 of 67 (2015-10-19 to 2016-09-30)

Subject Matters

Subject Matter Details

Legislative Proposal, Bill or Resolution

Legislative Proposal, Bill or Resolution, Policies or Program

Policies or Program

Policies or Program, Regulation

Regulation

Communication Techniques

Government Institutions

Description of activities

Responsible officer name and position during the period of this registration

Government funding

In-house Corporation Contact Information

Parent Company Information

Subsidiary Beneficiary Information

Senior Officers whose lobbying activities represent less than 20% of their Duties

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties